Breaking News

AIBioTech Acquires ImmunoTox

By Kristin Brooks | March 21, 2014

Adds biopharma assessment services

AIBioTech has acquired ImmunoTox Inc., a contract research company that provides immunotoxicology and immunopharmacology studies for the pharma, biopharma, and manufacturing sectors. The acquisition expands AIBioTech’s biotechnology services for examining the effects of drugs, chemicals, biologics, and other physical agents on the immune system. ImmunoTox will operate as a division of AIBioTech.
Founder and chief executive officer of ImmunoTox, Inc., Kimber White, Ph.D. said, "We are looking forward to the opportunities that come with aligning ourselves with AIBioTech. Our capabilities complement AIBioTech's existing assay design and immunology services very well."
Dr. White will continue to serve as a consultant for AIBioTech. Other key employees of ImmunoTox have accepted positions and together with the acquisition of all necessary instrumentation, the ImmunoTox division will be able to continue its service offerings.
"We intend to leverage the expertise of ImmunoTox into expanded service offerings for our current customers including for the first time, flow cytometry," said AIBioTech president and chief scientific officer Robert B. Harris, Ph.D. "The ability to monitor the immune response of the host organism is a critical component along the path of drug (and chemical) development, and by adding these services to our research support repertoire, AIBioTech becomes even more competitive as the preferred full service contract research organization."

Related Contract Manufacturing:

blog comments powered by Disqus
  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • The Role of Alliances in Modern Drug Development

    The Role of Alliances in Modern Drug Development

    Dr. Claire Madden-Smith, Senior Vice President, Juniper Pharma Services||September 8, 2016
    Combining expertise to get drug candidates through development

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent